Eli Lilly and Company (NYSE:LLY) will spend roughly $700 million to build the Lilly Institute for Genetic Medicine in Boston’s Seaport neighborhood. The facility will focus on RNA- and DNA-based therapeutics and draw resources from Lilly’s 2020 acquisition of Prevail Therapeutics for approximately $1 billion. The new facility will be based in a 334,000 ft2…
Kyverna Therapeutics wins $85 million in Series B financing
The cell therapy company Kyverna Therapeutics (Emeryville, California) has closed an oversubscribed $85 million Series B funding round led by Northpond Ventures. The company plans to use the funding to launch a Phase 2 trial for its lead asset, KYV-101, in the first half of 2022. KYV-101 is an autologous anti-CD19 chimeric antigen receptor T-cell…
Intellia and Kyverna announce CAR-T pact
Genome editing company Intellia Therapeutics (NSDQ:NTLA) and cell therapy firm Kyverna Therapeutics have entered into a licensing and collaboration agreement to develop an allogeneic CD19 chimeric antigen receptor (CAR) T-cell therapy for various B cell-mediated autoimmune diseases. Under the terms of the agreement, Intellia (Cambridge, Massachusetts) will get an equity stake in Kyverna (Emeryville, California)…